Neurocrine Biosciences (NBIX) Revenue & Revenue Breakdown
Neurocrine Biosciences Revenue Highlights
Latest Revenue (Y)
$1.89B
Latest Revenue (Q)
$622.10M
Main Segment (Y)
Product
Neurocrine Biosciences Revenue by Period
Neurocrine Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.89B | 26.76% |
| 2022-12-31 | $1.49B | 31.34% |
| 2021-12-31 | $1.13B | 8.38% |
| 2020-12-31 | $1.05B | 32.71% |
| 2019-12-31 | $788.10M | 74.65% |
| 2018-12-31 | $451.24M | 179.19% |
| 2017-12-31 | $161.63M | 977.51% |
| 2016-12-31 | $15.00M | -24.12% |
| 2015-12-31 | $19.77M | 100.00% |
| 2014-12-31 | - | -100.00% |
| 2013-12-31 | $2.92M | -94.51% |
| 2012-12-31 | $53.14M | -31.36% |
| 2011-12-31 | $77.41M | 131.08% |
| 2010-12-31 | $33.50M | 1034.47% |
| 2009-12-31 | $2.95M | -25.71% |
| 2008-12-31 | $3.98M | 224.75% |
| 2007-12-31 | $1.22M | -96.88% |
| 2006-12-31 | $39.23M | -68.33% |
| 2005-12-31 | $123.89M | 45.45% |
| 2004-12-31 | $85.18M | -38.76% |
| 2003-12-31 | $139.08M | 670.73% |
| 2002-12-31 | $18.05M | -56.25% |
| 2001-12-31 | $41.24M | 182.71% |
| 2000-12-31 | $14.59M | -13.17% |
| 1999-12-31 | $16.80M | 5.00% |
| 1998-12-31 | $16.00M | -38.70% |
| 1997-12-31 | $26.10M | 35.94% |
| 1996-12-31 | $19.20M | - |
Neurocrine Biosciences generated $1.89B in revenue during NA 2023, up 26.76% compared to the previous quarter, and up 418.20% compared to the same period a year ago.
Neurocrine Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $622.10M | 5.40% |
| 2024-06-30 | $590.20M | 14.54% |
| 2024-03-31 | $515.30M | 0.02% |
| 2023-12-31 | $515.20M | 3.29% |
| 2023-09-30 | $498.80M | 10.18% |
| 2023-06-30 | $452.70M | 7.68% |
| 2023-03-31 | $420.40M | 2.04% |
| 2022-12-31 | $412.00M | 6.21% |
| 2022-09-30 | $387.90M | 2.56% |
| 2022-06-30 | $378.20M | 21.76% |
| 2022-03-31 | $310.60M | -0.45% |
| 2021-12-31 | $312.00M | 5.41% |
| 2021-09-30 | $296.00M | 2.46% |
| 2021-06-30 | $288.90M | 22.10% |
| 2021-03-31 | $236.60M | -4.56% |
| 2020-12-31 | $247.90M | -4.10% |
| 2020-09-30 | $258.50M | -14.52% |
| 2020-06-30 | $302.40M | 27.54% |
| 2020-03-31 | $237.10M | -2.87% |
| 2019-12-31 | $244.10M | 9.91% |
| 2019-09-30 | $222.09M | 20.98% |
| 2019-06-30 | $183.58M | 32.64% |
| 2019-03-31 | $138.40M | 5.26% |
| 2018-12-31 | $131.49M | -13.35% |
| 2018-09-30 | $151.76M | 56.60% |
| 2018-06-30 | $96.91M | 36.32% |
| 2018-03-31 | $71.09M | -24.79% |
| 2017-12-31 | $94.52M | 55.52% |
| 2017-09-30 | $60.77M | 859.34% |
| 2017-06-30 | $6.33M | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | -100.00% |
| 2016-03-31 | $15.00M | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | -100.00% |
| 2015-03-31 | $19.77M | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | -100.00% |
| 2013-12-31 | $730.00K | 0.14% |
| 2013-09-30 | $729.00K | -0.14% |
| 2013-06-30 | $730.00K | - |
| 2013-03-31 | $730.00K | -96.67% |
| 2012-12-31 | $21.95M | 134.55% |
| 2012-09-30 | $9.36M | -11.47% |
| 2012-06-30 | $10.57M | -6.20% |
| 2012-03-31 | $11.27M | 1.41% |
| 2011-12-31 | $11.11M | -73.32% |
| 2011-09-30 | $41.63M | 242.47% |
| 2011-06-30 | $12.16M | -2.84% |
| 2011-03-31 | $12.51M | -8.38% |
| 2010-12-31 | $13.66M | -5.47% |
| 2010-09-30 | $14.45M | 211.18% |
| 2010-06-30 | $4.64M | 516.60% |
| 2010-03-31 | $753.00K | 1.76% |
| 2009-12-31 | $740.00K | 0.95% |
| 2009-09-30 | $733.00K | - |
| 2009-06-30 | $733.00K | -1.87% |
| 2009-03-31 | $747.00K | 2.47% |
| 2008-12-31 | $729.00K | -4.20% |
| 2008-09-30 | $761.00K | 3.68% |
| 2008-06-30 | $734.00K | -58.08% |
| 2008-03-31 | $1.75M | - |
Neurocrine Biosciences generated $622.10M in revenue during Q3 2024, up 5.40% compared to the previous quarter, and up 137.42% compared to the same period a year ago.
Neurocrine Biosciences Revenue Breakdown
Neurocrine Biosciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product | $1.86B | $1.44B | $1.09B | $994.10M | $752.90M |
| Collaboration Revenue | $26.50M | $47.80M | $43.40M | $51.80M | $35.19M |
Neurocrine Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (98.60%), and Collaboration Revenue (1.40%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $616.60M | $583.80M | $509.00M | $507.20M | $491.80M | $446.30M | $415.30M | $404.60M | $379.30M | $352.00M | $305.00M | $303.50M | $288.80M | $231.00M | $241.30M | $254.10M | $267.60M | $231.10M | $237.83M | - |
| Collaboration Revenue | $5.50M | $6.40M | $6.30M | $8.00M | $7.00M | $6.40M | $5.10M | $7.40M | $8.60M | $26.20M | $5.60M | $8.50M | $7.20M | $22.10M | $5.60M | $6.60M | $4.40M | $34.80M | $6.18M | - |
Neurocrine Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (99.12%), and Collaboration Revenue (0.88%).
Neurocrine Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NBIX | Neurocrine Biosciences | $1.89B | $622.10M |
| ALKS | Alkermes | $1.66B | $378.14M |
| PBH | Prestige Consumer Healthcare | $1.13B | $267.14M |
| EVO | Evotec SE | $781.43M | $208.73M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| SUPN | Supernus Pharmaceuticals | $607.52M | $168.32M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $175.38M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DVAX | Dynavax | $232.28M | $73.80M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| AVDL | Avadel Pharmaceuticals | $27.96M | $41.50M |
NBIX Revenue FAQ
What is Neurocrine Biosciences’s yearly revenue?
Neurocrine Biosciences's yearly revenue for 2023 was $1.89B, representing an increase of 26.76% compared to 2022. The company's yearly revenue for 2022 was $1.49B, representing an increase of 31.34% compared to 2021. NBIX's yearly revenue for 2021 was $1.13B, representing an increase of 8.38% compared to 2020.
What is Neurocrine Biosciences’s quarterly revenue?
Neurocrine Biosciences's quarterly revenue for Q3 2024 was $622.1M, a 5.40% increase from the previous quarter (Q2 2024), and a 24.72% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $590.2M, a 14.54% increase from the previous quarter (Q1 2024), and a 30.37% increase year-over-year (Q2 2023). NBIX's quarterly revenue for Q1 2024 was $515.3M, a 0.02% increase from the previous quarter (Q4 2023), and a 22.57% increase year-over-year (Q1 2023).
What is Neurocrine Biosciences’s revenue growth rate?
Neurocrine Biosciences's revenue growth rate for the last 3 years (2021-2023) was 66.48%, and for the last 5 years (2019-2023) was 139.45%.
What are Neurocrine Biosciences’s revenue streams?
Neurocrine Biosciences's revenue streams in c 23 are Product, and Collaboration Revenue. Product generated $1.86B in revenue, accounting 98.60% of the company's total revenue, up 29.13% year-over-year. Collaboration Revenue generated $26.5M in revenue, accounting 1.40% of the company's total revenue, down -44.56% year-over-year.
What is Neurocrine Biosciences’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Neurocrine Biosciences was Product. This segment made a revenue of $1.86B, representing 98.60% of the company's total revenue.